Inflammatory bowel disease: the function of metalloproteinases
DOI:
https://doi.org/10.15584/ejcem.2018.4.13Keywords:
inflammatory bowel disease, matrix metalloproteinases, extracellular matrixAbstract
Introduction. Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.
Aim. The aim of this work was to review the current literature regarding matrix metalloproteinases. The databases such as PubMed, ScienceDirect and Springer were utilized to search the literature for relevant articles.
Material and methods. An analysis of literature. We collected information, data, and examples of the function of metalloproteinases.
Results. Herein we show that metalloproteinases play a role in such processes as the immune response, angiogenesis, the epithelial barrier function, fibrosis induced by the inflammatory process, and in the process of carcinogenesis.
Conclusion. Further studies on the role of metalloproteinases in the process of carcinogenesis associated with inflammatory bowel diseases are required.
Downloads
References
Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(1):177-183.
Fink K1, Boratyński J. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis. Postepy Hig Med Dosw (Online). 2012; 66:609-628.
Malemud CJ.Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696-1701.
Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009;158(3):983-994.
Velinov N, Poptodorov G, Gabrovski N, Gabrovski S. The role of matrixmetalloproteinases in the tumor growth and metastasis. Khirurgiia (Sofiia). 2010;(1):44-49.
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786–801.
Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61:198–223.
Hynes RO, Naba A. Overview of the matrisome—an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012;4:a004903.
Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol. 2010;341:126–140.
Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123:4195–4200.
Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA. 1962;48:1014–1022.
Herzog C, Haun RS, Ludwig A, Shah SV, Kaushal GP. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A. J Biol Chem. 2014;289:13308–13322.
Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nature Rev Immunol. 2013;13:649–665.
Simon-Assmann P, Kedinger M, De Arcangelis A, Rousseau V, Simo P. Extracellular matrix components in intestinal development. Experientia. 1995;51:883–900.
Biancheri P, Giuffrida P, Docena GH. The role of transforming growth factor (TGF)-β in modulating the immune response and fibrogenesis in the gut. Cytokine Growth Factor Rev. 2013;25:45–55.
Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16:558–564.
Hrabec E, Naduk J, Stręk M, Hrabec Z. Kolagenazy typu IV (MMP-2 i MMP-9) i ich substraty — białka macierzy pozakomórkowej, hormony, cytokiny i ich receptory. Post Biochem. 2007;53:37-45.
Meng L, Uzui H, Guo H, Tada H. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep. 2018;17(5):6887-6892.
Tokai N, Yoshida S, Kotani T, et al. Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis. PLoS One. 2018;13(8):e0202601.
Sohail A, Marco M, Zhao H, et al. Characterization of the dimerization interface of membrane type 4 (MT4)-matrix metalloproteinase. J Biol Chem. 286: 33178-33189.
Sorsa T, Tervahartiala T, Leppilahti J, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovas- cular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011;63:108-113.
Derosa G, D’Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metal- loproteinase-1 in patients with hypertension. Endothelium. 2006;13:227-231.
Rodriguez JA, Orbe J, Martinez de Lizarrondo S, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling pro- moted by inflammatory stimuli. Front Biosci. 2008;13:2916-2921.
Suomela S, Koljonen V, Skoog T, Kukko H, Böhling T, Saarialho-Kere U. Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma. Virchows Arch. 2009; 455: 495-503.
Koelink PJ, Overbeek SA, Braber S, et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut. 2014;63(4):578-587.
Schaefer L, Reinhardt DP. Special issue: Extracellular matrix: Therapeutic tools and targets in cancer treatment. Adv Drug Deliv Rev. 2016;97:1-3.
Fujimoto K, Nakajima K, Yaoita Y. Expression of matrix metalloproteinase genes in regressing or remodeling organs during amphibian metamorphosis. Dev Growth Differ. 2007;49:131–143.
Kim HY, Nelson CM. Extracellular matrix and cytoskeletal dynamics during branching morphogenesis. Organogenesis 2012;8:56–64.
Suomela S, Koljonen V, Skoog T, Kukko H, Böhling T, Saarialho-Kere U. Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma. Virchows Arch. 2009; 455: 495-503.
Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 2010;21:687–689.
Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech. 2014;7:193–203.
Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulonary fibrosis. Am J Pathol. 2011;179:1733-1745.
Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta. 2012;1824:133-145.
Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Med. 2011;17:320–329.
Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 2010;21:687–689.
Lee S, Park HI, Sang QX. Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion. Biochem J. 2007;403:31-42.
Ito E, Yana I, Fujita C, et al. The role of MT2-MMP in can cer progression. Biochem Biophys Res Commun. 2010;393:222-227.
Sohail A, Sun Q, Zhao H, Bernardo MM, Cho JA, Fridman R. MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane- anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev. 2008;27:289-302.
Taman H, Fenton CG, Hensel IV, Anderssen E, Florholmen J, Paulssen RH. Transcriptomic Landscape of Treatment-Naïve Ulcerative Colitis. J Crohns Colitis. 2018;12(3):327-336.
Krawczak K, Karczmarek-Borowska B, Maciąg M, Guz W. Rare case of slowly progressing lung cancer with colon metastases. Wiad Lek. 2017;70(1):148-151.
Volkov AM, Murashov IS, Polonskaya YV, et al. Changes of Content of Matrix Metalloproteinases and Their Tissue Expression in Various Types of Atherosclerotic Plaques. Kardiologiia. 2018;(10):12-18.
Zhai Y, Kuick R, Tipton C, et al. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. J Pathol. 2016;238(1):21-30.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
